Skip to main content

Advertisement

SpringerLink
Log in

Can cancer clinical trials be fixed?

  • News Feature
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

An Erratum to this article was published on 06 May 2011

This article has been updated

As oncology drug after oncology drug fails to achieve accelerated approval, sponsors are seeking other ways to speed trials. Malorye Allison investigates.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Change history

  • 09 February 2011

    In the version of the article originally published, it was stated that “Avastin was studied in combination with Taxol in all these trials, and compared to Taxol alone.” It should have read. “Avastin was studied in combination with chemotherapy.”In addition, it stated that the FDA had rescinded approval of Avastin for metastatic breast cancer. It should have read, the FDA “recommended removal of the breast cancer indication from the Avastin label…” The errors have been corrected in the HMTL and PDF versions of the article.

References

  1. Allison, M. Nat. Biotechnol. 28, 879–880 (2010).

    Article  CAS  Google Scholar 

  2. Merrill, J. The Pink Sheet Daily, Elsevier Business Intelligence, 27 August 2010.

    Google Scholar 

  3. Vogel, C.L. et al. J. Clin. Oncol. 27 Supplement, 1017 (2009).

    Google Scholar 

  4. Mulcahy, N. Medscape Today, <http://www.medscape.com/viewarticle/703912> 4 June 2009.

    Google Scholar 

  5. Bollag, G. et al. Nature 467, 596–599 (2010).

    Article  CAS  Google Scholar 

  6. Harmon, A. The New York Times, p. 1, 18 September 2010.

    Google Scholar 

  7. Soda, M. et al. Nature 448, 561–566 (2007).

    Article  CAS  Google Scholar 

  8. Anonymous. Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products (FDA, March 2004). <http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm077262.htm>

  9. Anonymous. Qualification Process for Drug Development Tools. Draft Guidance (US Department of Health and Human Services, FDA, CDER, October 2010). <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM230597.pdf>

  10. Allison, M. Nat. Biotechnol. 28, 383–384 (2010).

    Article  CAS  Google Scholar 

  11. Richey, E.A. et al. J. Clin. Oncol. 27, 4398–4405 (2009).

    Article  CAS  Google Scholar 

  12. Lanthier, M. & Sridhara, R. J. Clin. Oncol. 28, e226 (2010).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Acton, Massachusetts

    Malorye Allison

Authors
  1. Malorye Allison
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Allison, M. Can cancer clinical trials be fixed?. Nat Biotechnol 29, 13–15 (2011). https://doi.org/10.1038/nbt.1746

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.1746

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation